HAFNER, Philipp, KELLER, Steffen Johannes, CHEN, Xun, ALRAWASHDEH, Asma, JUMAA, Huda, NOLLMANN, Friederike Inga, BESSON, Solène, KEMMING, Judith, GORKA, Oliver, DAS, Tonmoy, APPIAH, Bismark, LEHMANN, Ariane, LI, Mujia, BENGSCH, Bertram, ZEISER, Robert, THOLEN, Stefan, SCHILLING, Oliver, GROSS, Olaf, VLACHOS, Andreas, WITTEL, Uwe Alexander, ELVERFELDT, Dominik von, REICHARDT, Wilfried, BÖRRIES, Melanie, GEOFFROY, Andrieux, FICHTNER-FEIGL, Stefan, HANNIBAL, Luciana und RUESS, Dietrich Alexander, 2026. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Freiburg: Universität.

Hafner, P., Keller, S.J., Chen, X., Alrawashdeh, A., Jumaa, H., Nollmann, F.I., Besson, S., Kemming, J., Gorka, O., Das, T., Appiah, B., Lehmann, A., Li, M., Bengsch, B., Zeiser, R., Tholen, S., Schilling, O., Groß, O., Vlachos, A., Wittel, U.A., Elverfeldt, D. von, Reichardt, W., Börries, M., Geoffroy, A., Fichtner-Feigl, S., Hannibal, L., Ruess, D.A., 2026. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Universität, Freiburg. https://doi.org/10.1038/s41392-025-02563-7

Hafner, P., Keller, S. J., Chen, X., Alrawashdeh, A., Jumaa, H., Nollmann, F. I., Besson, S., Kemming, J., Gorka, O., Das, T., Appiah, B., Lehmann, A., Li, M., Bengsch, B., Zeiser, R., Tholen, S., Schilling, O., Groß, O., Vlachos, A., Wittel, U. A., Elverfeldt, D. von, Reichardt, W., Börries, M., Geoffroy, A., Fichtner-Feigl, S., Hannibal, L., & Ruess, D. A. (ca. 2026). Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations [Cd]. Universität. https://doi.org/10.1038/s41392-025-02563-7

Hafner P, Keller SJ, Chen X, Alrawashdeh A, Jumaa H, Nollmann FI, Besson S, Kemming J, Gorka O, Das T, Appiah B, Lehmann A, Li M, Bengsch B, Zeiser R, Tholen S, Schilling O, Groß O, Vlachos A, Wittel UA, Elverfeldt D von, Reichardt W, Börries M, Geoffroy A, Fichtner-Feigl S, Hannibal L, Ruess DA (2026) Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Universität, Freiburg

Hafner, Philipp/ Keller, Steffen Johannes/ Chen, Xun/ Alrawashdeh, Asma/ Jumaa, Huda/ Nollmann, Friederike Inga/ Besson, Solène/ Kemming, Judith/ Gorka, Oliver/ Das, Tonmoy/ Appiah, Bismark/ Lehmann, Ariane/ Li, Mujia/ Bengsch, Bertram/ Zeiser, Robert/ Tholen, Stefan/ Schilling, Oliver/ Groß, Olaf/ Vlachos, Andreas/ Wittel, Uwe Alexander/ Elverfeldt, Dominik von/ Reichardt, Wilfried/ Börries, Melanie/ Geoffroy, Andrieux/ Fichtner-Feigl, Stefan/ Hannibal, Luciana/ Ruess, Dietrich Alexander, Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations, Freiburg 2026.